AsymBio Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $358M

  • Investors
  • 2

AsymBio General Information

Description

Operator of biopharmaceutical development and manufacturing designed to support the discovery, development, and commercialisation of biologic therapeutics. The company offers drugability evaluation, antibody and recombinant protein development, conjugate development, mRNA development, analytical science, quality control, and regulatory support capabilities, enabling biotechnology companies and pharmaceutical organizations to accelerate biologic drug development and regulatory readiness.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, Building 1
  • Number 518 Haoye Road
  • Shanghai, 201203
  • China
+86 021
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Corporate Office
  • 4th Floor, Building 1
  • Number 518 Haoye Road
  • Shanghai, 201203
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AsymBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 12-Oct-2022 $358M Completed Startup
To view AsymBio’s complete valuation and funding history, request access »

AsymBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AsymBio Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
GL Ventures Venture Capital Minority
Trinity Innovation Fund Venture Capital Minority
To view AsymBio’s complete investors history, request access »

AsymBio Investments (1)

AsymBio’s most recent deal was a IPO with Evopoint Biosciences for . The deal was made on 16-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Evopoint Biosciences 16-Sep-2026 IPO Drug Discovery
To view AsymBio’s complete investments history, request access »

AsymBio FAQs

  • When was AsymBio founded?

    AsymBio was founded in 2022.

  • Where is AsymBio headquartered?

    AsymBio is headquartered in Shanghai, China.

  • What is the size of AsymBio?

    AsymBio has 9 total employees.

  • What industry is AsymBio in?

    AsymBio’s primary industry is Biotechnology.

  • Is AsymBio a private or public company?

    AsymBio is a Private company.

  • What is AsymBio’s current revenue?

    The current revenue for AsymBio is .

  • How much funding has AsymBio raised over time?

    AsymBio has raised $358M.

  • Who are AsymBio’s investors?

    GL Ventures and Trinity Innovation Fund have invested in AsymBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process